3.5 Endocrine Pharmacology, Diabetic Care & Bone Metabolism Agents

3.5 Endocrine Pharmacology, Diabetic Care & Bone Metabolism Agents

Core Board Principle: Endocrine disorders significantly alter host inflammatory responses, bone turnover kinetics, and tissue healing capacity. Dental hygienists must recognize clinical markers of glycemic control, execute emergency protocols for acute hypoglycemic episodes, manage steroid-dependent patients, and implement rigorous preventive measures for patients undergoing antiresorptive therapy to prevent MRONJ.

Endocrine pharmacology spans conditions commonly encountered in the dental hygiene clinic, including Diabetes Mellitus, thyroid imbalances, adrenal insufficiency, and bone density disorders. Mastery of these pharmacological agents and their oral ramifications ensures patient safety and optimal clinical decision-making.

---

1. Diabetes Mellitus: Pathophysiology & Pharmacotherapy

Diabetes Mellitus (DM) is a metabolic disorder characterized by chronic hyperglycemia resulting from defects in insulin secretion, insulin action, or both.

+----------------------------------------------------------------------------------------+
|                              TYPE 1 VS TYPE 2 DIABETES MELLITUS                        |
+-----------------------+----------------------------------+-----------------------------+
| FEATURE               | TYPE 1 DIABETES (T1DM)           | TYPE 2 DIABETES (T2DM)      |
+-----------------------+----------------------------------+-----------------------------+
| Etiology              | Autoimmune destruction of        | Peripheral insulin resistance|
|                       | pancreatic beta cells            | & progressive beta cell loss|
| Insulin Production    | Absolute insulin deficiency      | Relative deficiency         |
| Ketoacidosis Risk     | High (Diabetic Ketoacidosis DKA) | Low (Hyperosmolar State)    |
| Primary Pharmacotherapy| Subcutaneous Injectable Insulins | Oral Hypoglycemics & GLP-1s |
+-----------------------+----------------------------------+-----------------------------+

Diagnostic & Monitoring Parameters

• Glycated Hemoglobin ($HbA_1c$): Measures the percentage of hemoglobin bound to glucose, reflecting average blood glucose over the preceding 2 to 3 months (120-day lifespan of red blood cells).
  • Normal: $< 5.7%$
  • Prediabetes: $5.7% - 6.4%$
  • Diabetes Diagnosis: $\ge 6.5%$
  • ADA Target for Diabetic Patients: $< 7.0%$ (Well-controlled). Patients with $HbA_1c > 8.0%$ exhibit impaired polymorphonuclear (PMN) neutrophil function, leading to accelerated periodontal destruction, recurrent abscesses, and delayed post-operative healing.

Pharmacological Agents

1. Injectable Insulins: Rapid-acting (Lispro, Aspart), Short-acting (Regular), Intermediate-acting (NPH), and Long-acting (Glargine/Lantus, Detemir).
2. Oral Antidiabetic Medications:
   • Biguanides (Metformin / Glucophage): First-line agent for T2DM. Decreases hepatic gluconeogenesis and increases peripheral insulin sensitivity. Does NOT stimulate insulin release and therefore carries minimal risk of hypoglycemia when used as monotherapy.
   • Sulfonylureas (Glipizide, Glyburide, Glimepiride): Stimulate insulin release from pancreatic beta cells. Carry a high risk of inducing hypoglycemia.
   • SGLT2 Inhibitors (Empagliflozin): Block renal glucose reabsorption in proximal tubules.
   • GLP-1 Receptor Agonists (Semaglutide, Dulaglutide): Injectable or oral agents that enhance glucose-dependent insulin secretion and delay gastric emptying.

---

2. Dental Hygiene Management & Hypoglycemic Emergencies

Clinical Management Protocol

• Schedule morning appointments after the patient has eaten a normal breakfast and taken their scheduled antidiabetic medication.
• Confirm blood glucose level before starting invasive procedures (Target: $80-130 \text{ mg/dL}$ fasting; $< 180 \text{ mg/dL}$ post-prandial).

Acute Hypoglycemia Protocol ("Rule of 15")

Hypoglycemia (blood glucose $< 70 \text{ mg/dL}$) is the most common medical emergency associated with diabetic dental patients. Early signs include diaphoresis (sweating), tremors, tachycardia, anxiety, confusion, and dizziness.

+-----------------------------------------------------------------------------------+
|                         HYPOGLYCEMIC EMERGENCY MANAGEMENT                         |
+-----------------------------------------------------------------------------------+
| 1. CONSCIOUS PATIENT:                                                             |
|    - Immediately stop dental treatment.                                           |
|    - Administer 15 grams of fast-acting oral carbohydrate                        |
|      (e.g., 4 oz orange juice, 3-4 glucose tablets, 1 tube glucose gel).          |
|    - Wait 15 minutes and re-test blood glucose.                                   |
|    - If glucose remains <70 mg/dL, repeat 15 grams of carbohydrate.               |
| 2. UNCONSCIOUS PATIENT:                                                           |
|    - Call 911 / EMS immediately.                                                  |
|    - Administer Intramuscular (IM) Glucagon (1 mg) or IV 50% Dextrose.            |
+-----------------------------------------------------------------------------------+

---

3. Thyroid & Adrenal Gland Therapeutics

Thyroid Therapeutics

• Hypothyroidism (Hashimoto's Thyroiditis, Myxedema, Cretinism): Managed with synthetic levothyroxine (Synthroid). Patients exhibit cold intolerance, weight gain, fatigue, macroglossia, and delayed tooth eruption.
• Hyperthyroidism (Graves' Disease, Thyrotoxicosis): Managed with Methimazole, Propylthiouracil (PTU), or radioactive iodine ($\text{I}^{131}$). Patients exhibit heat intolerance, exophthalmos, tachycardia, and weight loss.

  EPINEPHRINE CONTRAINDICATION: Local anesthetic vasoconstrictors (epinephrine) are strictly CONTRAINDICATED in patients with uncontrolled hyperthyroidism due to the risk of triggering a life-threatening Thyroid Storm (severe tachycardia, hyperthermia, malignant hypertension, and agitation).

Corticosteroid Therapeutics & Adrenal Insufficiency

• Glucocorticoids (Prednisone, Hydrocortisone, Dexamethasone) possess potent anti-inflammatory and immunosuppressive properties.
• Primary Adrenal Insufficiency (Addison's Disease): Underproduction of cortisol and aldosterone, causing hyperpigmentation of skin and oral mucosa (bronzing).
• Secondary Adrenal Insufficiency: Caused by prolonged exogenous corticosteroid therapy suppressing the Hypothalamic-Pituitary-Adrenal (HPA) axis.

  RULE OF TWOS (Historical Benchmark): Adrenal suppression should be suspected if a patient has taken 20 mg of hydrocortisone (or equivalent) daily for 2 continuous weeks within the past 2 years. Patients exposed to severe surgical stress may require supplemental steroid coverage to prevent acute Adrenal Crisis (profound hypotension and shock).

---

4. Bone Metabolism & Antiresorptive Pharmacology (MRONJ)

Antiresorptive Agents

• Bisphosphonates (Oral: Alendronate/Fosamax, Risedronate; IV: Zoledronic Acid/Zometa, Pamidronate): Ingested by osteoclasts during bone resorption, inhibiting the farnesyl pyrophosphate synthase enzyme, impairing osteoclast function and inducing osteoclast apoptosis. Used for osteoporosis, Paget's disease, and bone metastases.
• RANKL Inhibitors (Denosumab / Prolia): Monoclonal antibody that binds to RANKL, preventing osteoclast maturation.

Medication-Related Osteonecrosis of the Jaw (MRONJ)

MRONJ is a severe adverse drug effect characterized by exposed bone in the maxillofacial region that persists for more than 8 weeks in a patient with a history of antiresorptive or antiangiogenic therapy and no history of radiation therapy to the jaws.

+--------------------------------------------------------------------------------------+
|                              MRONJ DIAGNOSTIC CRITERIA                               |
+--------------------------------------------------------------------------------------+
| 1. Current or previous treatment with antiresorptive or antiangiogenic agents.        |
| 2. Exposed bone or bone probed through an intra/extraoral fistula for >8 weeks.      |
| 3. No history of radiation therapy to the jaws or obvious metastatic disease.        |
+--------------------------------------------------------------------------------------+

• Risk Factors: Intravenous bisphosphonates (significantly higher risk than oral forms), duration of therapy $>3$ years, invasive dental procedures (extractions, periodontal surgery), and mandibles with tori.
• Clinical Protocols: All necessary invasive dental procedures (extractions, surgery) should be completed BEFORE initiating IV bisphosphonate therapy. For patients already on long-term antiresorptive therapy, emphasize non-surgical periodontal maintenance, meticulous hygiene, and conservative endodontic management to avoid extractions.